Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine plus high-dose interferon beta-1a in relapsing-remitting multiple sclerosis
2008-000955-90Phase 2Active
- Sponsor
- IRCCS Mondino Foundation
- Start
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in multiple sclerosis (MS) comparing Interferon beta-1a + N-acetylcysteine with Interferon beta-1a + placebo (2 arms). Primary endpoints: Safety and efficacy of N-acetylcysteine plus interferon beta-1a versus interferon beta-1a plus placebo and Effect on neurodegeneration by MRI spectroscopy. Started Mar 2008; status: active.
02
Drugs
acetylcysteine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2008-000955-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000955-90.